AN2 Therapeutics, Inc.
ANTX
$5.73
-$0.25-4.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.19M | -10.03M | -8.71M | -9.35M | -6.46M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 878.00K | 1.38M | 1.28M | 590.00K | 1.70M |
| Change in Net Operating Assets | 309.00K | -3.42M | 2.19M | 2.39M | -2.84M |
| Cash from Operations | -7.00M | -12.07M | -5.24M | -6.38M | -7.60M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.66M | 8.29M | 7.17M | 6.11M | 5.83M |
| Cash from Investing | -3.66M | 8.29M | 7.17M | 6.11M | 5.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.74M | 37.33M | 0.00 | 48.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -248.00K | -- | -- | -- | -- |
| Cash from Financing | 1.49M | 37.33M | 0.00 | 48.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.17M | 33.55M | 1.94M | -217.00K | -1.77M |